Relay Therapeutics Q3 2026: Loss Narrows, $848.6M Runway to 2029

As seen on the 24/7 Wall St. homepage on November 4, 2026.

RLAY Relay Therapeutics
Q3 2026
EPS
-$0.37
est -$0.40 +7.8%
Revenue
$0K
est $2M -100.0%

A $848.6 million cash pile funds operations into 2029, well past the mid-2027 Phase 3 enrollment completion for zovegalisib in breast cancer. The loss narrowed versus consensus even with one-time lease termination costs from exiting One Kendall Square. Vascular anomalies data lands at ASH on December 14.

Continue ReadingShow less

Relay Therapeutics posted a Q3 2026 GAAP loss of $0.37 per share, beating the consensus estimate of roughly $0.40, even after absorbing one-time costs tied to the termination of its operating lease at One Kendall Square, which ran through both the research and general expense lines. Revenue came in at zero against analyst expectations of $1.58 million, missing expectations in a way that reflects Relay's status as a clinical-stage company with no commercial products of its own.

Research and development spending rose to $77.1 million, driven primarily by expanded clinical activity behind zovegalisib, the company's lead PI3K-alpha inhibitor. General and administrative expenses also moved higher, again partly due to the lease termination costs, while interest income rose and partially softened the cash outflow.

Relay ended the quarter with $848.6 million in cash, equivalents, and investments, a runway the company expects to carry it into 2029. That matters because the most important near-term clinical milestone, completion of enrollment in the Phase 3 ReDiscover-2 trial of zovegalisib in second-line breast cancer, is targeted for mid-2027, well inside that window. A planned frontline breast cancer Phase 3 trial combining zovegalisib with atirmociclib is expected to begin in early 2027, with a regulatory design update anticipated by year-end 2026.

Sponsored

CEO Sanjiv Patel pointed to Pfizer's FourLight-1 trial data as supporting the case for a CDK4-selective approach, which underpins Relay's combination strategy with atirmociclib. He also noted the hire of Shannon Campbell as Head of Commercial, a signal that the company is beginning to build infrastructure for a potential launch even while trials are still enrolling.

The next concrete catalyst is December 14, when updated ReInspire data for zovegalisib in PIK3CA-driven vascular malformations will be presented orally at the American Society of Hematology meeting (Abstract 878). Relay has separately flagged an estimated 170,000 vascular anomaly patients per year in the U.S. as a potential addressable population, alongside PI3K-alpha-mutated HR-positive, HER2-negative breast cancer patients, underscoring why the pipeline's breadth matters to the long-term investment case.

Mentioned: RLAY